Stage selection for neoadjuvant radiotherapy in non-cervical esophageal cancer: A propensity score-matched study based on the SEER database

Ke Ma*1, Yong Yang2*, Shuai Wang1, Xiaodong Yang1, Tao Lu1, Junjie Xi1, Wei Jiang1, Cheng Zhan1, Yimeng Zhu2 & Qun Wang1

1 Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
2 Department of Thoracic Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University Suzhou, Jiangsu, China

Keywords
Neoadjuvant radiotherapy; non-cervical esophageal cancer; propensity score matching study; stage.

Correspondence
Cheng Zhan, Department of Thoracic Surgery, Zhongshan Hospital of Fudan University, No. 180, Fenglin Road, Shanghai 200032, China.
Tel: 86 21 6404 1990
Fax: 86 21 6404 1990
Email: czhan10@fudan.edu.cn

Yimeng Zhu, Department of Thoracic Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu 215001, China.
Tel: 86 512 6900 9090
Fax: 86 512 6900 9090
Email: zhuym_suzhou@126.com

*Ke Ma and Yong Yang contributed equally to this work.

Received: 7 April 2018;
Accepted: 27 May 2018.

doi: 10.1111/1759-7714.12794
Thoracic Cancer 9 (2018) 1111–1120

Introduction
In the past decade, esophageal carcinoma, which involves a poor prognosis, has become the sixth most common cancer.1 The main histological types of esophageal cancer include squamous cell carcinoma and adenocarcinoma, and > 95% esophageal cancers are located in the non-cervical esophagus.2 Treatment strategies are similar for both types of esophageal cancer, and include surgery, chemotherapy, and radiotherapy. For early stage and thoracic or abdominal esophageal cancer, surgical resection is the primary option, while definitive chemoradiotherapy is utilized more often in advanced or cervical esophageal cancer. Currently, neoadjuvant chemoradiotherapy (NCRT) has gradually gained clinical acceptance, but has the potential for degrading the staging of primary tumors, and is thus controversial, especially neoadjuvant radiotherapy (NRT).3 Though NRT can reduce the size of a local tumor and make it possible to perform surgery, NRT might also
increase the risk of postoperative complications, which are associated with a poor prognosis. Furthermore, the stage of non-cervical esophageal cancer that would result in a greater benefit from NRT has not been established, and no research based on a large population has determined the correlation between NRT and prognosis in patients with esophageal cancer. All these factors limit the application of NRT in the treatment of non-cervical esophageal cancer, and additional evidence is needed to demonstrate its effects.

Propensity score-matched (PSM) analysis, which was defined by Rosenbaum and Rubin and has been increasingly applied to medical research, is a method for reducing treatment selection bias by adjusting for variables related to exposure and pretreatment confounding, which might affect outcomes in non-randomized studies. In the current study we compared the overall survival of patients with thoracic or abdominal esophageal squamous cell carcinoma (ESCC)/esophageal adenocarcinoma (EAC) who underwent surgery with or without NRT based on the data from the SEER Epidemiology, and End Results [SEER (http://seer.cancer.gov/)] database after applying the PSM method to provide evidence for NRT in the treatment of esophageal cancer.

**Study population**

The data used in the current study was selected from the SEER database, which is freely available to the public (https://seer.cancer.gov/). The SEER program of the National Cancer Institute is an authoritative source of information on the incidence and prevalence of cancer, mortality rates, population-based variables, primary tumor characteristics, and treatment, and covers approximately 28% of the US population.

SEER*Stat software was used to screen the population for the current study. The patients with T2 and T3 stage non-cervical esophageal cancer who had accurate TNM records and underwent surgical resection between 2004 and 2014 were enrolled in the study. We did not include T1 and T4 stages that lacked adequate statistics in this research. Patients who did not undergo radical surgery or did not have ESCC nor EAC histological types were excluded from the study. Patients with M1 stage or patients who underwent peri- or postoperative radiotherapy were excluded from the study. Patients with M1 stage or patients who underwent peri- or postoperative radiotherapy were

**Patients and Methods**

**Study population**

The data used in the current study was selected from the SEER database, which is freely available to the public (https://seer.cancer.gov/). The SEER program of the National Cancer Institute is an authoritative source of information on the incidence and prevalence of cancer, mortality rates, population-based variables, primary tumor characteristics, and treatment, and covers approximately 28% of the US population.

SEER*Stat software was used to screen the population for the current study. The patients with T2 and T3 stage non-cervical esophageal cancer who had accurate TNM records and underwent surgical resection between 2004 and 2014 were enrolled in the study. We did not include T1 and T4 stages that lacked adequate statistics in this research. Patients who did not undergo radical surgery or did not have ESCC nor EAC histological types were excluded from the study. Patients with M1 stage or patients who underwent peri- or postoperative radiotherapy were excluded from the study. Patients with M1 stage or patients who underwent peri- or postoperative radiotherapy were

**Study population**

The data used in the current study was selected from the SEER database, which is freely available to the public (https://seer.cancer.gov/). The SEER program of the National Cancer Institute is an authoritative source of information on the incidence and prevalence of cancer, mortality rates, population-based variables, primary tumor characteristics, and treatment, and covers approximately 28% of the US population.

SEER*Stat software was used to screen the population for the current study. The patients with T2 and T3 stage non-cervical esophageal cancer who had accurate TNM records and underwent surgical resection between 2004 and 2014 were enrolled in the study. We did not include T1 and T4 stages that lacked adequate statistics in this research. Patients who did not undergo radical surgery or did not have ESCC nor EAC histological types were excluded from the study. Patients with M1 stage or patients who underwent peri- or postoperative radiotherapy were excluded from the study. Patients with M1 stage or patients who underwent peri- or postoperative radiotherapy were

**Study population**

The data used in the current study was selected from the SEER database, which is freely available to the public (https://seer.cancer.gov/). The SEER program of the National Cancer Institute is an authoritative source of information on the incidence and prevalence of cancer, mortality rates, population-based variables, primary tumor characteristics, and treatment, and covers approximately 28% of the US population.

SEER*Stat software was used to screen the population for the current study. The patients with T2 and T3 stage non-cervical esophageal cancer who had accurate TNM records and underwent surgical resection between 2004 and 2014 were enrolled in the study. We did not include T1 and T4 stages that lacked adequate statistics in this research. Patients who did not undergo radical surgery or did not have ESCC nor EAC histological types were excluded from the study. Patients with M1 stage or patients who underwent peri- or postoperative radiotherapy were excluded from the study. Patients with M1 stage or patients who underwent peri- or postoperative radiotherapy were

**Study population**

The data used in the current study was selected from the SEER database, which is freely available to the public (https://seer.cancer.gov/). The SEER program of the National Cancer Institute is an authoritative source of information on the incidence and prevalence of cancer, mortality rates, population-based variables, primary tumor characteristics, and treatment, and covers approximately 28% of the US population.

SEER*Stat software was used to screen the population for the current study. The patients with T2 and T3 stage non-cervical esophageal cancer who had accurate TNM records and underwent surgical resection between 2004 and 2014 were enrolled in the study. We did not include T1 and T4 stages that lacked adequate statistics in this research. Patients who did not undergo radical surgery or did not have ESCC nor EAC histological types were excluded from the study. Patients with M1 stage or patients who underwent peri- or postoperative radiotherapy were excluded from the study. Patients with M1 stage or patients who underwent peri- or postoperative radiotherapy were

**Study population**

The data used in the current study was selected from the SEER database, which is freely available to the public (https://seer.cancer.gov/). The SEER program of the National Cancer Institute is an authoritative source of information on the incidence and prevalence of cancer, mortality rates, population-based variables, primary tumor characteristics, and treatment, and covers approximately 28% of the US population.

SEER*Stat software was used to screen the population for the current study. The patients with T2 and T3 stage non-cervical esophageal cancer who had accurate TNM records and underwent surgical resection between 2004 and 2014 were enrolled in the study. We did not include T1 and T4 stages that lacked adequate statistics in this research. Patients who did not undergo radical surgery or did not have ESCC nor EAC histological types were excluded from the study. Patients with M1 stage or patients who underwent peri- or postoperative radiotherapy were excluded from the study. Patients with M1 stage or patients who underwent peri- or postoperative radiotherapy were
also excluded. Information on age, sex, race, marital status, insurance status, primary site of tumor, pathological grade, histological type, TNM stage, radiotherapy status, and survival were collected for each case from the SEER database. The 7th edition of the TNM staging system for esophageal cancer was used as a reference in the study.6

Statistical analysis

All cases were divided into two groups on the basis of histological types (ESCC and EAC), and split into two subgroups by the presence or absence of NRT. Each pair of subgroups was matched for other baseline variables, which would confound comparisons by PSM. These variables included age, sex, race, marital status, insurance status, primary site of tumor, pathologic grade, T stage and lymph node involvement status. All cases in both groups with NRT plus surgery (NRS) were matched at a 2:1 ratio to cases with surgery alone (SA) using the nearest neighbor match method with a 0.1 standard deviation caliper width.7

Survival curves of the presence or absence of NRT for T2 and T3 stages in the ESCC and EAC groups were evaluated using the Kaplan-Meier method. Furthermore, according to positive or negative pathological involvement of lymph nodes in T2 and T3 stages, we drew another two pairs of survival curves. Each pair of curves were compared using the stratified log-rank test and a P-value <0.05 was considered to represent statistical significance. PSM analysis was performed using the MatchIt package (https://cran.r-project.org/web/packages/MatchIt/index), while the Kaplan-Meier method and log-rank test were performed using the survival package in R project 3.4.2 (http://www.r-project.org). SPSS 24.0 software (IBM Corporation, Armonk, NY, USA) was used for the remaining statistical analyses.

Results

A group of 8797 patients with esophageal cancer and TNM stage records who underwent beam radiation between 2004–2014 were identified by SEER*Stat. A total of 1631

| Characteristics          | Original Data Set | Matched Data Set |
|--------------------------|-------------------|------------------|
|                         | NRS (%) | SA (%) | Sdiff | P* Value | NRS (%) | SA (%) | Sdiff | P* Value |
| Total                    | 252     | 93     | 0.163 | 0.108    | 150     | 75     | 0.186 | 0.018    |
| Age(year)                |          |        |       |          |          |        |       |
| <60                      | 102 (40.5) | 30 (32.3) | 0.172 | 44 (29.3) | 30 (40.0) | 0.186 |        |
| ≥60                      | 150 (59.5) | 63 (67.7) | 0.172 | 106 (70.7) | 45 (60.0) | 0.186 |        |
| Gender                   |          |        |       |          |          |        |       |
| Male                     | 158 (62.7) | 53 (57.0) | 0.096 | 90 (60.0) | 44 (58.7) | 0.022 |        |
| Female                   | 94 (37.3)  | 40 (43.0) | 0.096 | 60 (40.0) | 31 (41.3) | 0.022 |        |
| Race                     |          |        |       |          |          |        |       |
| White                    | 187 (74.2) | 63 (67.7) | 0.118 | 111 (74.0) | 54 (72.0) | 0.036 |        |
| Others                   | 65 (25.8)  | 30 (32.3) | 0.118 | 39 (26.0) | 21 (28.0) | 0.036 |        |
| Insurance status         |          |        |       |          |          |        |       |
| Insured                  | 178 (70.7) | 55 (59.1) | 0.201 | 102 (68.0) | 51 (68.0) | 0.000 |        |
| Others                   | 74 (29.4)  | 38 (40.9) | 0.201 | 48 (32.0) | 24 (32.0) | 0.000 |        |
| Marital status           |          |        |       |          |          |        |       |
| Married                  | 140 (55.6) | 48 (51.6) | 0.066 | 85 (56.7) | 42 (56.0) | 0.092 |        |
| Others                   | 112 (44.4) | 45 (48.4) | 0.065 | 65 (43.3) | 33 (44.0) |        |
| Primary site             |          |        |       |          |          |        |       |
| Thoracic                 | 133 (52.8) | 47 (50.5) | 0.036 | 77 (51.3) | 40 (53.3) | 0.032 |        |
| Abdominal                | 119 (47.2) | 46 (49.5) | 0.036 | 73 (48.7) | 35 (46.7) | 0.032 |        |
| Pathologic grade         |          |        |       |          |          |        |       |
| I                        | 16 (6.4)  | 9 (9.7)  | 0.123 | 8 (5.3)  | 5 (6.7)  | 0.056 |        |
| II                       | 141 (56.0) | 49 (52.7) | 0.066 | 91 (60.7) | 42 (56.0) | 0.049 |        |
| III                      | 94 (37.3)  | 34 (36.6) | 0.015 | 50 (33.3) | 28 (37.3) | 0.008 |        |
| IV                       | 1 (0.4)   | 1 (1.1)  | 0.078 | 1 (0.7)  | 0 (0)    | 0.015 |        |
| T stage                  |          |        |       |          |          |        |       |
| T2                       | 59 (23.4) | 35 (37.6) | 0.126 | 45 (30.0) | 26 (34.7) | 0.082 |        |
| T3                       | 193 (76.6) | 58 (62.4) | 0.126 | 105 (70.0) | 49 (65.3) | 0.082 |        |
| Involvement of lymph node|          |        |       |          |          |        |       |
| Negative                 | 96 (38.1) | 58 (62.4) | 0.408 | 71 (47.3) | 40 (53.3) | 0.098 |        |
| Positive                 | 156 (61.9) | 35 (37.6) | 0.408 | 79 (52.7) | 35 (46.7) | 0.098 |        |

*P value for chi-square test. NRS, Neoadjuvant radiotherapy plus surgery; SA, Surgery alone; Sdiff, Standardized differences.
patients, which included 345 patients with ESCC and 1286 patients with EAC were enrolled in the study after selection. The selection process is shown in Fig 1.

### Propensity score-matching

Based on the original data, 252 patients (73.0%) with ESCC and 1070 patients (83.2%) with EAC underwent NRT. Among the ESCC patients, the distribution of NRS and SA showed a statistical significance in T and N stage and insurance status. A similar difference in distribution was detected with respect to age, T and N stage, insurance status, and marital status in patients with EAC. In both the ESCC and EAC groups, all characteristics not included in the Kaplan-Meier survival analysis were matched by PSM between the NRS and SA subgroups at a 2:1 ratio. The mirror histograms of propensity scores for patients stratified by therapy status were shown in Fig 2. The distribution of these baseline variables was appropriately balanced in the matched data set, which was detected by chi-square testing for both the ESCC (Table 1) and EAC groups (Table 2). All of the significant differences in the aforementioned distribution were decreased after matching, and chi-square testing in each line list of baseline characteristics showed a P-value >0.05. Additionally, the balance in the baseline variables in both original data set and matched data set were validated by limited standardized difference.

### Survival analysis

The overall survival curves of NRS versus SA before and after matching are shown in Fig 2. No significant differences were detected in each pair of curves in the ESCC (Fig 3a,b) and EAC groups (Fig 3c,d). The overall survival curve of NRS was nearly in agreement with SA in the ESCC group. In the EAC group, the 1 and 2 year survivals of NRS were better than SA, but the two subgroups had a similar survival rate > 3 years postoperatively.
To explore the relationship between NRS and stage of esophageal cancer, further survival analysis was carried out based on T2 and T3 stages. The Kaplan-Meier curves and log-rank test showed no statistical significance between the prognoses of ESCC patients with T2 and T3 stages who underwent NRS or SA (Fig 4a,b). In the EAC group, there was no significant difference in the T2 stage (Fig 4c); however, the T3 stage EAC patients would benefit from NRS ($P = 0.011$, Fig 4d).

In consideration of the fact that it is difficult to examine positive lymph nodes without a pathological diagnosis of surgical specimens preoperatively, which leads to N stage confusion; the T stage was the only basis for primary grouping in the current study. It is easy to confirm positive involvement of lymph nodes by preoperative imaging, thus the status of lymph node involvement based on each T stage was divided into two parts (N0 and N+). A comparison of survival curves in each subgroup is shown in Fig 5, 6. NRS improves the prognosis of T3N+ stage of EAC ($P = 0.0052$, Fig 6d), while NRS showed no significant benefit in overall survival for the other subgroups (Fig 5a–d, 6a–c).
Discussion

This study focused on comparing the prognosis of patients who had undergone esophagectomy alone versus surgery with NRT in patients with non-cervical ESCC and EAC T2 and T3 stages based on a large sample size and the PSM method. Finally, we found that NRT was only associated with a better prognosis in patients with EAC T3N+ stage. Compared with surgical resection alone, another analysis showed that the overall survival in ESCC and other stages of EAC did not benefit from NRT.

However, there is several major limitations in this manuscript that should be noted. Since the preoperative chemotherapy details were not recorded in SEER database, some of the patients analyzed in our manuscript might also have received neoadjuvant chemotherapy. NRT strategy was not recommended by North American, Europe, or Japanese guidelines, therefore it is likely that the NRT patients might have some unmeasured confounders, just like comorbidity or body weight loss, which made their treatment physicians chose the non-recommended NRT instead.

Figure 4 Overall Kaplan-Meier survival curve according to different histological type and stage including (a) ESCC T2, (b) ESCC T3, (c) EAC T2 and (d) EAC T3. NRS, neoadjuvant radiotherapy plus surgery; SA, surgery alone.
of recommended NCRT. These unmeasured confounders made the analyses in the current manuscript biased and the results must be further validated.

In recent decades, a small number of studies have focused on the effect of NRT in patients with esophageal cancer. In a randomized clinical trial based on 206 thoracic ESCC patients, there was no advantage in 3 and 5 year survival compared to surgery alone. A clinical trial by Arnott et al., including 56 patients with ESCC and 114 patients with EAC, also reported similar overall survival in patients who received NRT and those managed by SA. The result of two phase III trials also showed that NRT along with surgery had no value in improving resectability and overall survival in patients with esophageal cancer. However, few studies have investigated the relationship between stage of esophageal cancer and NRT.

Currently, the majority of studies have compared the prognosis of NCRT with surgical resection versus SA. In combination with chemotherapy, NCRT has shown a potential survival benefit in a series of studies, but these

Figure 5 Overall Kaplan-Meier survival curve according to status of lymph node involvement in T2 and T3 stage of ESCC including (a) T2N0, (b) T2N+, (c) T3N0 and (d) T3N+. NRS, neoadjuvant radiotherapy plus surgery; SA, surgery alone.
studies were heterogenous in terms of histological type, tumor stage, and therapeutic regimens. In a phase III trial by Tepper et al., cisplatin and fluorouracil concurrently with radiotherapy before resection reflected survival advantages in both ESCC and EAC patients. Another study by Walsh et al. reported that NCRT was superior to resection alone with a similar regimen. A generic regimen of neoadjuvant therapy for both ESCC and EAC was proposed by van Hagen et al. that included cisplatin and paclitaxel (six cycles) and concurrent radiotherapy (41.4 Gy) based on a trial with 368 patients. However, there are also several studies or clinical trials that have failed to demonstrate the statistical significance between NCRT and SA.

Only a few studies have focused on the correlation between NRT or NCRT and stage of esophageal cancer. For early stage esophageal cancer, a trial by Nygaard et al. involving 108 stage T1 and T2 ESCC patients did not show overall survival after NRT. A phase III trial based on 195 patients revealed that NCRT did not improve the R0
resection rate or survival, but increased the postoperative mortality in stage I and II esophageal cancer. Different results were obtained following NCRT in patients with advanced esophageal cancer. A study involving 193 patients with ESCC concluded that a pathological complete response to NCRT was critical for improving survival in T3 stage, while another study based on 214 patients with T₂N₁ EAC suggested that NCRT was not a significant determinant of overall survival or disease-free survival. Due to a lack of evidence, there was no consensus on which stage of esophageal cancer should be appropriate for neoadjuvant therapy.

Recently, the National Comprehensive Cancer Network (NCCN) guidelines for esophageal and esophagogastric junction cancer suggested that ESCC and EAC patients with T₁p-T₄a, N₀ to N₁, and M₀ stages receive preoperative chemoradiation, while the European Society for Medical Oncology (ESMO) guidelines showed that ESCC and EAC patients with T₃ to T₄ or N₁ to N₃ with M₀ stages should undergo NCRT. In the clinical guidelines edited by the Japan Esophageal Society, NCRT was not recommended as preoperative therapy for any histological type. In the current study, evidence of NRT for specific stages of esophageal cancer was provided. Unlike any guidelines mentioned, the results of this research suggested a limited benefit of NRT in EAC patients with esophageal cancer T₃N+ stage, and NRT did not show an advantage in prognosis in any other stages. An accurate assessment for staging should be evaluated before neoadjuvant therapy.

Compared with SA, neoadjuvant therapy may add to the risk of toxicity. The potential complications, which included pneumonia, acute respiratory distress syndrome, anastomotic leakage, and cardiac complications, were mainly caused by radiotherapy. In a study of Bosch et al., a significant increase in cardiopulmonary complications was observed in the neoadjuvant therapy group. Moreover, in a phase III trial, more postoperative deaths were demonstrated in patients treated by chemoradiotherapy preoperatively. Although postoperative radiation-related complications would be reduced with the development of radiotherapy, such as application of stereotactic body radiation, it was also necessary to evaluate the cardiopulmonary function of patients for the design and modification of radiation dosage.

There are several other limitations in this study. Because preoperative radiation dose and postoperative complication data were not available in the SEER database, even though it was a population-based database, we could not explore the relationship between dose and stage and compare the risk of complications in the PRS and SA groups. In addition, the current study was a retrospective study. What’s more, we only focused on treatment mortality but not life quality in this analysis as the data of life quality were not provided by SEER.

Conclusions

Compared with SA, NRT followed by resection had a significant survival benefit in non-cervical EAC patients with T₃N₁ stage. For patients with ESCC and other EAC stages, NRT versus SA did not demonstrate a statistical significant survival difference.

Acknowledgments

This work was supported by the Research Program of Shanghai Health and Family Planning Commission (201640102) (www.wsjsw.gov.cn), the Suzhou Industry Technology Innovation Program (SYSD2017172) (www.szkj.gov.cn), and the Shanghai Sailing Program (NO. 17YF1402400) (www.stcsm.gov.cn). We would like to thank International Science Editing Co. for editing the language.

Disclosure

The authors have no conflicts of interest to declare.

References

1 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
2 Tachimori Y, Ozawa S, Numasaki H et al. Comprehensive registry of esophageal cancer in Japan, 2010. Esophagus 2017; 14: 189–214.
3 Taylor MD, LaPar DJ, Davis JP et al. Induction chemoradiotherapy and surgery for esophageal cancer: Survival benefit with downstaging. Ann Thorac Surg 2013; 96: 225–30.
4 Wilke TJ, Bhirud AR, Lin C. A review of the impact of preoperative chemoradiotherapy on outcome and postoperative complications in esophageal cancer patients. Am J Clin Oncol 2015; 38: 415–21.
5 Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399–424.
6 Talsma K, van Hagen P, Grootenhuis BA et al. Comparison of the 6th and 7th editions of the UICC-AJCC TNM classification for esophageal cancer. Ann Surg Oncol 2012; 19: 2142–8.
7 Austin PC. The use of propensity score methods with survival or time-to-event outcomes: Reporting measures of effect similar to those used in randomized experiments. Stat Med 2014; 33: 1242–58.
8 Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28: 3083–107.
Stage selection for NRT in esophageal cancer

K. Ma et al.

9 Wang M, Gu XZ, Yin WB et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: Report on 206 patients. *Int J Radiat Oncol Biol Phys* 1989; 16: 325–7.

10 Arnott SJ, Duncan W, Kerr GR et al. Low dose preoperative radiotherapy for carcinoma of the oesophagus: Results of a randomized clinical trial. *Radiother Oncol* 1992; 24: 108–13.

11 Gignoux M, Roussel A, Paillot B et al. The value of preoperative radiotherapy in esophageal cancer: Results of a study of the E.O.R.T.C. *World J Surg* 1987; 11: 426–32.

12 Launois B, Delarue D, Campion JP et al. Preoperative radiotherapy for carcinoma of the esophagus. *Surg Gynecol Obstet* 1981; 153: 690–2.

13 Tepper J, Krasna MJ, Niedzwiecki D et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol* 2008; 26: 1086–92.

14 Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. *N Engl J Med* 1996; 335: 462–7.

15 van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med* 2012; 366: 2074–84.

16 Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawerman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. *J Clin Oncol* 2001; 19: 305–13.

17 Lee JL, Park SI, Kim SB et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. *Ann Oncol* 2004; 15: 947–54.

18 Burmeister BH, Smithers BM, Gebski V et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. *Lancet Oncol* 2006; 5: 659–68.

19 Nygaard K, Hagen S, Hansen HS et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. *World J Surg* 1992; 16: 1104–9 1110.

20 Mariette C, Dahan L, Mornex F et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: Final analysis of randomized controlled phase III trial FFCD 9901. *J Clin Oncol* 2014; 32: 2416–22.

21 Saeki H, Morita M, Tsuda Y et al. Multimodal treatment strategy for clinical T3 thoracic esophageal cancer. *Ann Surg Oncol* 2013; 20: 4267–73.

22 Spicer JD, Stiles BM, Sudarshan M et al. Preoperative Chemoradiation therapy versus chemotherapy in patients undergoing modified En bloc Esophagectomy for locally advanced esophageal adenocarcinoma: Is radiotherapy beneficial? *Ann Thorac Surg* 2016; 101: 1262–9 1969-1970.

23 National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancer (Version 1.2018). http://www.nccn.org/.

24 Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D, ESMO Guidelines Committee. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2016; 27: v50–7.

25 Kuwano H, Nishimura Y, Oyama T et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan esophageal society. *Esophagus* 2015; 12: 1–30.

26 Wilke TJ, Bhirud AR, Lin C. A review of the impact of preoperative chemoradiotherapy on outcome and postoperative complications in esophageal cancer patients. *Am J Clin Oncol* 2015; 38: 415–21.

27 Bosch D, Muijs CT, Mul VE et al. Impact of neo-adjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients. *Ann Surg Oncol* 2014; 21: 605–11.

28 Bosset JF, Gignoux M, Triboulet JP et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. *N Engl J Med* 1997; 337: 161–7.

29 Wang SL, Liao Z, Vapourciyan AA et al. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. *Int J Radiat Oncol Biol Phys* 2006; 64: 692–9.